Clinical trial · Interventional
A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
A Phase II Study of F182112 Combined With Different Administration Regimens in Patients With Relapsed or Refractory Multiple Myeloma
NCT07312188CI-TRIAL-00099944recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a single - arm, multi - cohort, open - label, multi - center Phase II clinical study. It aims to evaluate the efficacy and safety of F182112 combined with different administration regimens in patients with relapsed or refractory multiple myeloma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| F182112+CD38 | Drug | — | UNRESOLVED |
| F182112+P | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- F182112 combined with different administration regimens
- description
- F182112 combined with different administration regimens
- interventionNames
- Drug: F182112+P
- Drug: F182112+CD38
Primary outcomes (1)
- measure
- Objective response rate (ORR)
- timeFrame
- up to 2 years
Secondary outcomes (5)
- measure
- Progression - Free Survival（PFS）
- timeFrame
- Up to 2 years
- measure
- Minimal Residual Disease - negative rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Be diagnosed with multiple myeloma according to the IMWG 2016 criteria. * The previous treatment regimen must contain lenalidomide (lenalidomide must be used continuously for at least 2 cycles) and a proteasome inhibitor. * Participants whose previous treatment regimen contained pomalidomide or who were intolerant to pomalidomide cannot be enrolled. * Have an ECOG performance status score of 0 - 2. * Meet at least one of the following measurable disease indicators: 1. Serum M - protein ≥ 5 g/L. 2. Urine M - protein ≥ 200 mg/24 h. 3. Serum free light chain (FLC) test: Involved FLC level ≥ 100 mg/L and abnormal serum free light chain ratio (\< 0.26 or \> 1.65). Exclusion Criteria: * Patients with primary light - chain amyloidosis or plasma cell leukemia . * Patients with symptoms of central nervous system involvement of multiple myeloma. * Patients with a history of other malignancies other than multiple myeloma within 3 years before the first dose. * Patients with active mucosal or visceral bleeding. * Patients who have previously received BCMA - targeted therapy.
References
Publications (0)
Data not yet available
No reference posted for this study.